Tryptamine Therapeutics Limited
TYPTF
$0.015
$0.000.00%
| Weiss Ratings | TYPTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | TYPTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TYPTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | TYPTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -25.00% | |||
| 30-Day Total Return | 33.93% | |||
| 60-Day Total Return | -40.00% | |||
| 90-Day Total Return | -25.00% | |||
| Year to Date Total Return | 35.14% | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -61.04% | |||
| 52-Week Low % Change | 2,042.86% | |||
| Price | TYPTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.04 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Aug 07, 2024 | |||
| 52-Week High Price (Date) | Nov 21, 2024 | |||
| Valuation | TYPTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 26.27M | |||
| Enterprise Value | 24.51M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.01 | |||
| Earnings Per Share Growth | -69.51% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 7.14 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.02 | |||
| Enterprise Value/EBITDA (TTM) | -9.40 | |||
| Enterprise Value/EBIT | -7.18 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | TYPTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.14B | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TYPTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 61 3 9092 0475 | |||
| Address | 697 Burke Road Camberwell, VIC 3124 | |||
| Website | www.tryptherapeutics.com | |||
| Country | Australia | |||
| Year Founded | 2019 | |||
| Profitability | TYPTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | TYPTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -- | |||
| Return on Equity | -- | |||
| Income Statement | TYPTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -- | |||
| Net Income (TTM) | -- | |||
| Net Income Avl. to Common (TTM) | -- | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -54.31% | |||
| EPS Diluted (TTM) | -- | |||
| EPS Diluted Growth (Q YOY) | 87.91% | |||
| Balance Sheet | TYPTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.78M | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 2.98M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 2.62M | |||
| Current Ratio (Q) | 4.549 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 3.28M | |||
| Total Current Liabilities (Q) | 655.60K | |||
| Total Debt (Q) | 30.80K | |||
| Total Liabilities (Q) | 655.60K | |||
| Total Common Equity (Q) | 2.62M | |||
| Cash Flow | TYPTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | -- | |||
| Net Change in Cash (TTM) | -- | |||
| Levered Free Cash Flow (TTM) | -- | |||
| Cash from Operations (TTM) | -- | |||
